Cullinan Therapeutics has an impressive ability to generate cash with a current cash balance of $664mn and a market cap of $1.08bn. Learn more on CGEM stock here.
Cullinan Therapeutics has seen a recent pullback in its shares, but they are still up 50% since mid-April. Find out a full investment analysis for CGEM stock.
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates.
Cullinan Oncology, Inc. (CGEM) while announcing that it has changed its name to Cullinan Therapeutics, Inc., said it decided to develop CLN-978 in autoimmune diseases, with systemic lupus erythematosus (SLE) as a first indication.
Cash Position: $468.3 million in cash and investments as of December 31, 2023, expected to fund operations into the second half of 2026.R&D Expenses: Increased
Cullinan remains on track to report additional solid tumor dose escalation data for CLN-619 in the second quarter of 2024 and recently received FDA clearance for an IND to evaluate CLN-619 in...
Owen Hughes, Accomplished Life Sciences Executive with Deep Experience Across Investing, Operations and Governance, Appointed as Independent Member of the...
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) surged 70.5% to close at $0.1330 on Thursday after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered direct offering.
Point Roberts, WA and Delta, BC - February 5, 2021 (Investorideas.com Newswire) Investorideas.com, a global news source and leading retail investor and trader r...